Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States

2021 ◽  
pp. 1-9
Author(s):  
Xiaomeng Yue ◽  
Ana L. Hincapie ◽  
Yuxiang Li ◽  
Jeff J. Guo
Keyword(s):  
United States ◽  
Cost Effectiveness ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
The United States ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia

2018 ◽  
Vol 11 (2) ◽  
pp. 27-37
Author(s):  
N. A. Avxentyev ◽  
M. Yu. Frolov ◽  
A. S. Makarov
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Medical Cost ◽  
Myeloid Leukemia ◽  
Line Treatment ◽  
Second Line ◽  
Second Line Therapy ◽  
Drug Reimbursement ◽  
Line Therapy ◽  
The Government

Ilmatinib is currently the most widely used tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia (CML) in Russia. When patients develop resistance or intolerance to imatinib, second generation tyrosine kinase inhibitors (Tkis) are used. in Russia, nilotinib, dasatinib and bosutinib are registered in second-line, however only dasatinib is included in the government drug reimbursement program.The aim of this study was to conduct a pharmacoeconomic comparison of nilotinib, dasatinib and bosutinib as second-line treatments for patients with CML from the Russian healthcare system perspective.Materials and methods. Using the clinical trial data we developed a Markov model of CML progression on nilotinib, dasatinib or bosutinib second-line therapy and calculated the medical costs per patient. Both costeffectiveness analysis and budget-impact analysis reflected the local practice and the drug reimbursement approval process.Results. The average medical cost (per year) for nilotinib (1 683 thousand rubles or US$27 075) was 8.4% lower than that for dasatinib and 35.2% lower than for bosutinib. The 4-year total medical cost of treatment with nilotinib was 4 372 thousand rubles (US$ 70 336), which was 13.9% lower compared to dasatinib and 37.3% lower compared to bosutinib. nilotinib also had a lower cost/effectiveness ratio (US$ 1 602, 1 910 and 2 537 per life month for nilotinib, dasatinib and bosutinib, respectively). The estimated number of patients in Russia who need second-line treatment for CML is 996 patients. if nilotinib were included in the Government Reimbursement Program, a saving of 771 million rubles (US$ 12,4 million) over four years would be reached.Conclusions. When compared with dasatinib or bosutinib, nilotinib is the cost-saving option for the second-line treatment of CML patients in Russia. 

1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1158-P
Author(s):  
ODETTE REIFSNIDER ◽  
PRATIK PIMPLE ◽  
MATTHEW J.D. STARGARDTER ◽  
SARAH BRAND ◽  
NIHAR DESAI ◽  
...  
Keyword(s):  
United States ◽  
Type 2 Diabetes ◽  
Cost Effectiveness ◽  
The United States ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Analysis of Elderly Patients with Chronic Myeloid Leukemia

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5449-5449
Author(s):  
Engin Kelkitli ◽  
Hakan Goker ◽  
Mehmet Turgut ◽  
Memis Hilmi Atay
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Elderly Patients ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Survival Rates ◽  
Second Line ◽  
Molecular Responses ◽  
Line Therapy

Abstract Aims We aimed to evaluate in clinical results >65 years with chronic myeloid leukemia (CML). Methods 191 CML patients treated with imatinib frontline were evaluated retrospectively. 56 patients who aged >65 years were included our study. The clinical characteristics and treatment outcomes of these patients were evaluated. Results A total of 56 patients (24 [57.1%] men, 32 [42.9%] women) were evaluated retrospectively. The median age of the patients was 72 years (range 66-92years). Of the patients, 56 (98.2%) were in the chronic phase and one (1.8%) were in the accelerated phase when diagnosed. All of patients (100%) were receiving imatinib as the first-line therapy. Imatinib treatment induced 51 (91.8%) complete hematological responses at 3 months, 29 (51.8 %) complete cytogenetic responses at 6 months and 37 (66.6%) major molecular responses at 12months. As a result, nilotinib and dasatinib were used in 28 (50%) patients as second-line therapy because of intolerance 5 (8.9%), primary and soconder unresponsiveness 14 (25%), 9 (16.1%) respectively. Second-line Tyrosine kinase inhibitors (TKI) induced 23 complete hematological responses (82.1%) at 3 months, and 20 major molecular responses (71.4%) at 12 months. Fifty-two of 56 patients (92.9%) are still alive. The 5 year median overall survival and progression free survival rates were 92% and 85% respectively. Conclusion The prognosis of CML patients has changed with Tyrosine kinase inhibitors (TKI). In our study, we found that the response rate and survival rates elderly patients were similar to the younger patients in the literature. Disclosures No relevant conflicts of interest to declare.

The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States

Cancer ◽  
2020 ◽  
Vol 127 (1) ◽  
pp. 93-102 ◽  
Author(s):  
Erlene K. Seymour ◽  
Julie J. Ruterbusch ◽  
Aaron N. Winn ◽  
Julie A. George ◽  
Jennifer L. Beebe‐Dimmer ◽  
...  
Keyword(s):  
United States ◽  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitors ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
The United States ◽  
Medicare Patients
Sign in / Sign up

Export Citation Format

Share Document